Switch theme
Sign up to access all valuation multiples
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.
2006
382
LTM Revenue $224M
LTM EBITDA $52.8M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Harrow has a last 12-month revenue of $224M and a last 12-month EBITDA of $52.8M.
In the most recent fiscal year, Harrow achieved revenue of $200M and an EBITDA of $20.0M.
Harrow expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harrow valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $130M | $200M | XXX | XXX | XXX |
| Gross Profit | $63.2M | $90.6M | XXX | XXX | XXX |
| Gross Margin | 49% | 45% | XXX | XXX | XXX |
| EBITDA | $10.0M | $20.0M | XXX | XXX | XXX |
| EBITDA Margin | 8% | 10% | XXX | XXX | XXX |
| Net Profit | -$14.1M | -$24.4M | XXX | XXX | XXX |
| Net Margin | -11% | -12% | XXX | XXX | XXX |
| Net Debt | $7.9M | $109M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Harrow's stock price is $24.
Harrow has current market cap of $870M, and EV of $1.1B.
See Harrow trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $870M | XXX | XXX | XXX | XXX | $-0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Harrow has market cap of $870M and EV of $1.1B.
Harrow's trades at 4.7x LTM EV/Revenue multiple, and 19.9x LTM EBITDA.
Analysts estimate Harrow's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Harrow and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 52.6x | XXX | XXX | XXX |
| P/E | -49.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHarrow's NTM/LTM revenue growth is 40%
Harrow's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Harrow's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Harrow's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Harrow and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 53% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 101% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 50% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 71% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harrow acquired XXX companies to date.
Last acquisition by Harrow was XXXXXXXX, XXXXX XXXXX XXXXXX . Harrow acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Harrow founded? | Harrow was founded in 2006. |
| Where is Harrow headquartered? | Harrow is headquartered in United States of America. |
| How many employees does Harrow have? | As of today, Harrow has 382 employees. |
| Who is the CEO of Harrow? | Harrow's CEO is Mr. Mark L. Baum. |
| Is Harrow publicy listed? | Yes, Harrow is a public company listed on NAS. |
| What is the stock symbol of Harrow? | Harrow trades under HROW ticker. |
| When did Harrow go public? | Harrow went public in 2007. |
| Who are competitors of Harrow? | Similar companies to Harrow include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Harrow? | Harrow's current market cap is $870M |
| What is the current revenue of Harrow? | Harrow's last 12-month revenue is $224M. |
| What is the current EBITDA of Harrow? | Harrow's last 12-month EBITDA is $52.8M. |
| What is the current EV/Revenue multiple of Harrow? | Current revenue multiple of Harrow is 4.7x. |
| What is the current EV/EBITDA multiple of Harrow? | Current EBITDA multiple of Harrow is 19.9x. |
| What is the current revenue growth of Harrow? | Harrow revenue growth between 2023 and 2024 was 53%. |
| Is Harrow profitable? | Yes, Harrow is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
